Plasma gamma-aminobutyric acid (pGABA) is an index of brain GABA activity and a peripheral marker of mood disorder. Previous research has indicated that pGABA is abnormally low in approximately 40% of patients symptomatic with primary unipolar depression. We have now measured pGABA in a series of patients with bipolar disorder. Blood samples for GABA determinations were collected soon after admission to hospital or clinic while patients were symptomatic. In both manic and depressed phase bipolar patients, mean levels of pGABA were Received January 28,1993; revised May 4, 1993; accepted May 24, 1993. Published 1993 by Elsevier Science Publishing Co., Inc.
significantly lower than in healthy control subjects. The distribution of pGABA in bipolar patients, whether manic or depressed, was similar to that in symptomatic unipolar depression, with 30% to 40% having pGABA levels lower than the control range. These data indicate that low pGABA is not specific to the depressed state, as it is also found in the manic phase of bipolar disorder. Low pGABA may represent a shared biologic correlate between bipolar and unipolar illness. fNeuropsychopharmacology 9: [125] [126] [127] [128] [129] [130] [131] [132] 1993] learned helplessness and olfactory bulbectomy animal models of depression, GABA agonists, including proga bide and muscimol, have an antidepressant profIle (Lloyd et al. 1983 (Lloyd et al. , 1987 . Also, a wide range of chroni cally administered antidepressant and antimanic treat ments, including tricyclic and atypical antidepressants, monoamine oxidase inhibitors, electroconvulsive shock, carbamazepine, valproic acid, and lithium, have been shown to "upregulate" GABA-B receptors in rat brain (Lloyd and Pichat 1985; Motohashi et al. 1989) , although some laboratories report difficulty replicating this fInding (Cross and Horton, 1989) .
In vivo GABA tissue levels in human brain corre late inversely with severity of symptoms of depression (Honig et al. 1989) . Post-mortem studies of suicides have generally revealed a low GABA state in these cases (Cross et al. 1988) . Cerebrospinal fluid (CSF) levels of GABA in symptomatic depressed patients are sig nifIcantly lower than controls in most (Gerner et al. 1984; Gold 1980; Gerner and Hare 1981; Kosa et a1. 1982 ), but not all published studies. Patients with ma nia are also reported to have low CSF GABA, although the comparison with controls failed to reach statistical signifIcance, perhaps due to small sample sizes (Gerner and Hare 1981 ).
The precise origin of plasma GABA (pGABA) in hu mans is diffi cult to prove. However, GABA is a very CNS-specifIc compound. Ninety-nine percent of total body GABA and 95% of its synthesizing enzyme glu tamic acid decarboxylase (GAD) is in brain and spinal cord (Zachmann et al. 1966) . Concentrations of GABA in brain are high (4 mmol), and GABA is synthesized from glutamate (100 mmol) at a rate of about 40 mmollhr, therefore providing a theoretical brain turn over time of about 6 minutes. By contrast, except for oviduct, islets of Langerhans and pineal, peripheral tis sue and organ GABA levels are in the micromolar range or lower (Erdo and Kiss, 1986) . Furthermore, the activ ity of GAD in the periphery is only 1% to 15% of that in brain (Fogel, 1986) .
Gamma-aminobutyric acid does not readily cross the blood-brain barrier (Krogsgaard-Larsen 1992; Lo scher 1982). Even when pGABA levels are elevated by fulminant hepatic failure in humans (Record et al. 1976) or portocaval shunting in rats (Mans et al. 1992 ), brain GABA levels and GABA receptor binding are unaltered.
There are no correlations between pGABA levels in he patic failure and grade of encephalopathy (Singh et al. 1985) or performance on psychometric tests (Losher et al. 1991) . Increased brain GABA "tone" in hepatic en cephalopathy probably derives from increased brain benzodiazepine-like compound concentrations in most cases (Basile et al. 1991) , with the origin of these ben zodiazepines yet to be elucidated.
Gamma-aminobutyric acid transport from brain ex tracellular fluid (ECF) to CSF occurs by passive diffusion (Davson 1976) . Uptake mechanisms for GABA from ECF by neurons and glia are extremely efficient, and concentrations of GABA in ECF are the lowest of any neurotransmitter yet measured (Drew et al. 1989) . Con centrations of GABA in ECF and CSF are comparable (120 vs. 100 nmol).
Gamma-aminobutyric acid is actively transported from CSF to plasma (Snodgrass and Lorenzo 1973; Loscher 1982) . Concentrations of GABA in plasma and CSF are remarkably similar (100 nmol) in healthy hu mans (Uhlhaas et al. 1986) , suggesting the absence of a gradient between these two compartments (Loscher and Schmidt 1984) .
Cerebrospinal fluid GABA is of brain origin, and there is a high correlation between CSF and pGABA levels in rats (Bohlen et al. 1979; Ferkany et al. 1979) , dogs (Loscher 1982) , and normal humans (Uhlhaas et al. 1986 ) (r = 0.67, 0.59, and 0.51 respectively, p < .01).
Pharmacologic manipulations that change brain levels of GABA also change pGABA levels in similar proportion (Loscher 1979; Ferkany et al. 1979; Bohlen et al. 1979) . Of particular interest is the fInding that pGABA increased after intracerebroventricular ad ministration of an inhibitor of GABA transaminase (GABA-T) but not after intraperitoneal administration NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.2 of the drug (Loscher 1979) . Also, increase in pGABA is seen after the increase in brain GABA (Apud et al. 1981) . Inhibition of GAD causes a decrease in pGABA (Ferkany et al. 1979) . Furthermore, it may be that the small amounts of GABA found in peripheral tissue are not derived from glutamate through GAD but rather from putrescine (Caron et al. 1988) .
Metabolism of pGABA is by GABA-T in the liver.
Activity of GABA-T in liver is almost as high as in brain.
Hepatic clearance of pGABA is very rapid such that within 4 minutes, 90% of an exogenous load has been cleared (Minuk 1986 ). Platelets also have significant GABA-T activity and an active uptake for GABA, but their role in peripheral GABA homeostasis is probably minor (Oset-Gasque et al. 1986 ).
Based on pool size, transport between pools, and GABA concentrations, a peripheral source for pGABA need not be invoked but cannot be entirely rul ed out ( Figure 1 ). The most parsimonious explanation for the known data is that pGABA is probably derived largely from brain and may possibly provide a useful periph· eral marker of brain GABA activity (Rundfeldt and Losher 1992). However, it is important to note that the precise origin of pGABA is not critical to its being a bio· logic marker. Even peripheral markers of psychiatric illness can be theoretically important and clinicall y useful.
Plasma GABA is signilicantly low in patients symp· tomatic with primary unipolar depression, with about 40% of patients having pGABA levels lower than 95% of controls (Petty et al. 1992) . In earlier studies, we reported pGABA levels to be high in patients with rna· nia and similar to control in bipolar depressed phase patients (Petty and Sherman 1982) . Plasma GABA is also low in recently detoxilied alcoholics (Coffman and Petty 1984). However, this work used a gas chromato· graphic assay for pGABA, which measures total GABA (free + conjugated). Berrettini et al. (1986) reported that drug-free euthymic bipolar patients had low pGABA when measured with a high-performance liquid chro· matography (HPLC) assay specifIc for free pGABA.
In the present study, we have measured free plasma levels of GABA using HPLC in a series of bipolar inpa· tients and outpatients who were symptomatic either in the manic or depressed phase at the time of study.
MATERIALS AND METHODS

Subjects
Subjects were recruited from consecutive admissions to the inpatient wards and outpatient clinic of the Psy · chiatry Service at the Dallas VA Medical Center. All provided written informed consent. Diagnoses were de· termined according to DSM-III-R criteria using the Control volunteers were screened with a SCID and the SClD-II (Spitzer et al. 1989 ) and were negative for history of Axis I or II diagnosis. Family history from the subject of psychiatric or neurological illness in first degree relatives was also negative. None had any med ical condition requiring ongoing treatment, and all were medication free for 1 month prior to sampling.
Within 3 days of intake, blood samples for pGABA determination were obtained between 0700 and 0900 hours by venipuncture, centrifuged promptly, and fro zen until assay at -70°C. Assays were performed within 6 months of sample collection.
Assay
Plasma GABA was determined, with minor modi6.ca tions, by the procedure of Hare and Manyam (1980) . The response is linear from 20 to 500 pmollml, with an intraassay coefficient of variation of 3.9% and an inter assay CV of 6.4%.
Statistical Analysis
Because of significant heterogeneity of variance in pGABA levels, group diff erences were assessed by means of the Kruskal-Wallis analysis of variance. Pair wise differences were then assessed by means of Dunn's test. Plasma GABA levels were categorized on the ba sis of being either less than or equal to a value of 100 pmollml or strictly great than 100 pmollml. This cate gory represents a natural cutoff with 94% of healthy con trols above this value. Chi-square analysis was used to assess for differences between groups on this categori cal variable, and pairwise diff erences were assessed tak ing into account corrections for multiple comparisons.
All multiple comparison procedures were made follow ing recommendations in Woolson (1987) .
RESULTS
Group Differences
Demographic and clinical variables for the sample are presented in Table 1 . Controls had a signi6.cantly lower mean score on the HDRS, but were otherwise compara ble to patients.
Plasma GABA levels for the three study groups are shown in Figure 2 . Nonparametric analysis of variance showed that the distribution of pGABA in the two pa tient groups was markedly different from control (Kruskal-Wallis test statistic = 15.00, P = .001). Group comparisons showed that controls differed signi6.cantly from both the bipolar depressed phase (p = .0004) and the bipolar manic phase (p = .05) groups. Data are presented as mean ± standard deviation.
Categorical Grouping
To utilize pGABA as a categorical test, we compared the groups on the basis of low pGABA, where low pGABA is deflned as being less than or equal to 100 pmol/mI. These group differences are shown in Figure  3 . Although only 6% of the control group had pGABA levels below 100 pmol/mI, 42% of the bipolar, depressed-phase and 29% of the manic-phase patients had levels below 100 pmol/mI. The diff erence between these proportions is highly signmcant (X2 = 15.97; P < .001) by chi-square analysis. Pairwise group com parison showed that the proportion of controls with low pGABA differed signiflcantly from the bipolar de pressed group (estimated diff erence in proportion = .36, 95% confldence interval .14 to .59), but not from the bipolar manic group (estimated diff erence in propor- 
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Plasma GAB A (pmol/ml) 100 o tion = .23, 95% confldence interval -.01 to .47). The two patient groups did not differ on levels of pGABA (estimated difference in proportions = .13, 95% confldence interval -.18 to .44).
Medication Effects
Of the 57 patients, 34 were medication free at the time of sampling, and 23 were either on a single psychotropic medication (n = 6) (lithium, antidepressants) or were on two or more drugs including nonpsychotropic medi· cations (n = 17). In the entire patient group, the medication-free patients did not differ from the medi· cated patients in pGABA levels (Table 2) . However, fur· ther analysis revealed a signilicant effect in the bipolar depressed group but not the bipolar manic group. ness in pedigrees. Evidence available to date suggests that low pGABA distinguishes about one third of bipo lar patients and is state independent. However, at this time there is some evidence of heritability because monozygotic twins have similar pGABA levels (r = 0.73, P < .01) (Berrettini et al. 1982 ), but no information on pedigree segregation. Additional research is needed to clarify these issues.
Nonnal Controls
Mean pGABA levels and the proportion of subjects with markedly low pGABA are comparable for symp tomatic bipolar and symptomatic unipolar patients (Petty et al. 1992) . This demonstrates that low pGABA as a biologic marker is not specibc to either unipolar or bipolar mood disorder but is seen in both in approx imately the same proportion. Although the clinical delineation of mood disorders for schizophrenic syn dromes was made approximately 80 years ago, the fur ther subdivision of mood disorders into unipolar and bipolar types was not widely accepted until about 20 The specificity of low pGABA for mood disorders appears to be rather robust. Schizophrenia, panic dis order, bulimia, anorexia, and generalized anxiety dis order are not associated with abnormal pGABA (Petty et al. 1982 (Petty et al. , 1988 , whereas 33% of nondepressed alco holics have low pGABA (Petty et al. 1992 ). However, there may be a close relationship between mood dis orders and alcoholism (Coryell et al. 1992 ).
There were several limitations to the present study.
First, 23 of the 57 patients studied were on some type of medication. However, as seen in the bipolar, de pressed-phase group, the patients off medication had significantly lower pGABA, and the effect of medica tion was not to lower pGABA levels. If anything, a more robust group difference would have resulted if only medication-free patients were included. Medication in the bipolar, depressed-phase group was more likely as sociated with normal plasma GABA. Whether this was due to chance or was a specific medication effect can not be determined.
Second, there was no systematic attempt to sub classify patients in the manic phase who had mixed symptoms. It is possible that the manic patients with lower pGABA levels were experiencing dysphoric ma- 
